Introduction
The disruption of the DNA methylation profile is a major hallmark of human cancer. 1, 2 Among the aberrant DNA methylation signatures of transformed cells there are two key events in tumorigenesis: the promoter CpG island hypermethylationassociated inactivation of tumor suppressor genes and the global hypomethylation of the cancer genome, which is probably linked to chromosomal instability and the reactivation of endoparasitic sequences. 1, 2 The large body of data concerning DNA methylation landscapes in human tumors whose clinical relevance has already been recognized 3 occurs in a scientific context where information about the altered DNA methylation patterns in other common disorders, 4 ,5 such as neurological 6 and cardiovascular 7 diseases, is still very scarce. Part of the explanation might relate to the distinct biological processes involved and the ease with which sample material can be acquired in the oncology arena, but the explanation may also concern technical aspects. In this regard, it is necessary to have standard and common methods for obtaining comprehensive DNA methylation profiles from different types of cells and tissues with user-friendly bioanalytical DNA methylation is the most studied epigenetic mark and CpG methylation is central to many biological processes and human diseases. Since cancer has highlighted the contribution to disease of aberrant DNA methylation patterns, such as the presence of promoter CpG island hypermethylation-associated silencing of tumor suppressor genes and global DNA hypomethylation defects, their importance will surely become apparent in other pathologies. However, advances in obtaining comprehensive DNA methylomes are hampered by the high cost and time-consuming aspects of the single nucleotide methods currently available for whole genome DNA methylation analyses. Following the success of the standard CpG methylation microarrays for 1,505 CpG sites and 27,000 CpG sites, we have validated in vivo the newly developed 450,000 (450K) cytosine microarray (Illumina). The 450K microarray includes CpG and CNG sites, CpG islands/shores/shelves/open sea, non-coding RNA (microRNAs and long non-coding RNAs) and sites surrounding the transcription start sites (-200 bp to -1,500 bp, 5'-UTRs and exons 1) for coding genes, but also for the corresponding gene bodies and 3'-UTRs, in addition to intergenic regions derived from GWAS studies. Herein, we demonstrate that the 450K DNA methylation array can consistently and significantly detect CpG methylation changes in the HCT-116 colorectal cancer cell line in comparison with normal colon mucosa or HCT-116 cells with defective DNA methyltransferases (DKO). The provided validation highlights the potential use of the 450K DNA methylation microarray as a useful tool for ongoing and newly designed epigenome projects.
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome tools that allow data to be shared among scientists with distinct areas of expertise.
Looking at DNA methylation analysis technologies it is evident that a wide range of options exists. The bisulfite genomic sequencing of multiple clones is a useful approach for the detailed study of the CpG methylation status of a given sequence in a few samples, whilst methylation-specific PCR or pyrosequencing techniques are of great value for studying a few CpG sites in a greater number of samples. If we go to the global scale, available approaches include the isolation of methylated fractions of the genome by methylation-sensitive enzymes, [8] [9] [10] immunoprecipitation with a methyl-CpG binding domain antibody 11, 12 and methylcytosine antibody. [13] [14] [15] [16] New approaches include representation bisulphite sequencing (RRBS), 17 and sequencing-by-synthesis (MethylC-Seq) technology. 18 Using whole-genome bisulfite sequencing, an analysis of the DNA methylome of peripheral blood mononuclear cells from a single case has also been reported recently. 19 However, these techniques require a high level of specialization and are still expensive and time-consuming. Thus, they are a largely unavailable to a large part of the biomedical community who wish to examine the relevance of extensive ©2 0 1 1 L a n d e s B i o s c i e n c e .
D o n o t d i s t r i b u t e . [20] [21] [22] [23] and 27,000 CpG (Illumina Infinium HumanMethylation27 BeadChip), [24] [25] [26] [27] microarrays have proved to be useful for addressing various biological and medical questions in a range of independent studies in areas such as cancer, 23 ,24 aging 21,25-27 and tissue-specificity. 21, 22 The launch of a new 450,000 CpG site platform for DNA methylation studies (Illumina Infinium HumanMethylation450 BeadChip) appears to be a promising tool in the field. Herein, we have validated the 450K DNA methylation microarray from biological, functional and technical standpoints using colorectal cancer and DNA methylation models. The data obtained indicate that this new platform is a robust and reliable approach that may advance our understanding of the contribution of DNA methylation to human biology and its disorders. 
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Validation of the 450K DNA methylation microarray in colorectal tumorigenesis. We decided to test the ability of the 450K array to detect CpG methylation changes in a well defined model of colon cancer and DNA methylation. [28] [29] [30] [31] [32] [33] [34] [35] We did this in two ways. First, we compared the DNA methylation profiles of two human primary normal colorectal mucosa samples with that observed in a widely used colorectal cancer cell line, HCT-116. Second, we took advantage of the fact that homologous recombination has been used in HCT-116 to disrupt DNMT1 and DNMT3b in this system. 29 Most importantly, the HCT-116 double-knockout cells for DNMT1 and DNMT3b (DKO cells) have minimal DNA methyltransferase activity, a 95% reduction in 5-methylcytosine content, demethylation of repeated sequences and loss of imprinting at the insulin-like growth factor II locus. 29 Interestingly, DKO cells also display abrogation of the methylation-mediated silencing of many tumor suppressor coding genes [29] [30] [31] [32] 34 and non-coding RNAs with growth inhibitory functions such as microRNAs 33 and transcribed ultraconserved regions (T-UCRs). 35 Before analyzing the CpG methylation data, we excluded possible sources of technical bias that could have influenced the results. Every b value in the Infinium HumanMethylation450 BeadChip platform is accompanied by a detection p-value. We found that a threshold p-value above 0.01 indicated unreliable b values in 796 CpGs (0.16%) of the 485,764 sites analyzed. Thus, using this filter, 484,968 CpGs proved to be reliable and were used subsequently in the study.
described transcription start site and in the 5'-untranslated region (49, 525) 
genome (including intergenic regions) with a value of 67-70% (448 and 483 CpGs) (Figs. 2 and 3) . For those few hypomethylation events observed in the proximal promoters of cancer cells (165 and 174 CpGs), most of them (61%) occurred in non-CpG island-associated promoters (Fig. 5) . There was not any special association between the DNA methylation events and the type of related transcript or the chromosomal location: both hyper-and hypomethylation changes occurred in mRNA, ncRNA and non-RNA-associated CpG sites (Figs. 2 and 3 ) and all human chromosomes presented the two types of DNA methylation events (Figs. 2 and 3) . CNG methylation of the 3,343 sites included in the 450K microarray was not observed in the normal colon mucosa samples or in HCT-116 cells. Our approach to biological validation of the robustness of the 450K microarray data revealed promoter CpG island hypermethylation of sequences previously described as densely methylated in the HCT-116 cancer cell line using candidate, genomic and transcriptional approaches and further confirmed by bisulfite genomic sequencing of multiple clones and other techniques. [29] [30] [31] [32] 34 For example, this was the case for the 5'-CpG islands of the tumor suppressor genes SFRP2 and SFRP5, 30 CHFR, 36 45 Further biological validation of the new platform was provided by the DNA methylation status of imprinted and germline-specific genes in both normal colon mucosas. We observed that the 450K 450K DNA methylation analysis of normal mucosa and colon cancer cells. The first 450K DNA methylation comparisons were made between the two normal colon mucosa samples (NC1 and NC2) and the colorectal cancer cell line HCT-116. The results are summarized for NC1/HCT-116 in Figure 2 and for NC2/HCT-116 in Figure 3 . The data obtained from both comparison pairs are extremely similar, being partly associated with the high concordance of the 450K DNA methylation pattern between the two normal colon tissues (Pearson correlation coefficient R 2 = 0.9532 and Spearman's rank correlation coefficient rho = 0.9739) (Fig. 4) . Of the 484,968 CpGs studied, significant DNA methylation differences were observed between normal colon mucosa and colorectal cancer cells at 3-6% of the sites (17,884 and 29,784 CpGs) (Figs. 2 and 3) . Most importantly, 96-97% (17,190 and 29,112 CpGs) of the observed DNA methylation changes corresponded to a CpG hypermethylation event in the cancer cells, whilst hypomethylation changes only accounted for 2-4% (672 and 694 CpGs) of the total observed in HCT-116 (Figs. 2 and 3) . The difference between gain or loss of DNA methylation was not only quantitative, but also qualitative. CpG hypermethylation events in the colorectal cancer cells mostly occurred in CpG islands (66-68%; 11,784 and 19,372 CpGs) and proximal promoters (54-56%; 9,720 and 15,792 CpGs) (Figs. 2 and 3) . If we combine both concepts, 69-71% (6,894 and 10,843 CpGs) of the hypermethylated CpG site events in cancer cells occurred in proximal promoters that contained a CpG island (Fig. 5) . On the other hand, the DNA hypomethylation events mainly occurred in the body of the genes (38-40%; 253 and 277 CpGs) and in the Open Sea areas of the 
regulation (p = 1.5 x 10 -45 ). Conversely, CpGs hypomethylated in HCT-116 cells relative to normal colon involved 336 genes. These HCT-116 hypomethylated genes were significantly enriched in pathways associated with the regulation of cell communication (p = 0.0055) and system development (p = 0.0260).
Finally, we provide additional technical validation of the 450K DNA methylation microarray data in HCT-116 cells by comparing them with results from the well established and fully standardized 1,505 CpGs (GoldenGate), [20] [21] [22] and 27,000 CpG (Illumina Infinium HumanMethylation27 BeadChip), 26, 27 methylation microarrays. The HumanMethylation450 BeadChip includes 95% and 90% of the content contained on the Golden Gate and HumanMethylation27 BeadChip, respectively. We observed that DNA methylation data obtained with the new 450K microarray is correlated with the methylation levels detected at each CpG site using the 1,505 CpGs (Pearson correlation coefficient R 2 = 0.8721 and Spearman's rank correlation coefficient rho = 0.8615) and 27,000 CpG (Pearson correlation CpGs located in the differentially methylated regions (DMRs) of imprinted genes, such as H19, KCNQ1, SNRPN and MEST, presented 50% CpG methylation, as expected from the parental allele-specific methylation. 46 In addition, 450K CpGs located in the proximal promoter regions of male germline-specific genes, such as the MAGE and GAGE families, showed 100% CpG methylation in normal colon mucosa, as has been previously described for non-testicular tissues. 47 We were also interested in the overall type of genes that undergo DNA methylation changes in HCT-116 in comparison to normal colon mucosa. In order to identify functions associated with these differentially methylated CpGs and genes, we performed gene ontology (GO) analysis using the DAVID program (BROAD). The CpGs identified as being hypermethylated in the colon cancer cell line were associated with 4,763 genes. These genes were highly significantly enriched in cell and organ morphogenesis (p = 1.2 x 10 -29 and p = 1.3 x 10 -34 , respectively), regulation of RNA metabolic processes and transcriptional 
CpGs), promoters (33.2%, 36,718 CpG) and intergenic regions (30.2%, 33,368 CpGs) (Fig. 7) . With respect to the CpG content and neighborhood context, the over-representation of hypomethylated CpG sites in the shore regions (25.7%, 28,464 CpGs) (Fig. 7) is particularly noteworthy. As an additional internal control, the 450K microarray also detected the loss of promoter CpG island hypermethylation of the previously reported hypermethylated tumor suppressor coding genes in DKO cells [29] [30] [31] [32] 34 and non-coding RNAs. 33, 35 Interestingly, there were 191,000 (74.3%) CpG sites that had a methylation loss below the threshold of the 0.33-fold change in b values. Several explanations for this observation can be proposed, such as the suggested hypomorphic nature of the disrupted DNMT1 locus in DKO cells 48, 49 or the role of other DNA methyltransferases (such as DNMT3a) in maintaining the DNA methylation status of these CpG sites. 50 coefficient R 2 = 0.9379 and Spearman's rank correlation coefficient rho = 0.8770) microarrays (Fig. 6) . These results highlight the reliability of this novel DNA methylation platform.
450K DNA methylation analysis of HCT-116 and DKO cells. The in vivo validation of the 450K DNA methylation microarray was confirmed using the aforementioned isogenic cell line with the double defect in DNMT1 and DNMT3B (DKO cell line). 29 HCT-116 cells had 301,067 CpGs methylated over a basal b value of 0.66, while DKO cells showed a 51% reduction (146,834 CpGs retained the described methylation values) (Fig. 7) . When we analyzed HCT-116 in comparison with DKO for each CpG position, taking a 0.33-fold change in b values as the cut-off, we observed that 110,611 (37%) CpGs sites were hypomethylated in DKO cells (Fig. 7) . These demethylated CpG sites were widely distributed throughout the genome, affecting gene bodies (33.3%, 36,870 
Further functional validation of the 450K DNA methylation data was obtained by confronting CpG methylation status and gene expression in HCT-116 and DKO cells. Using the GeneChip Human Gene 1.0ST Array platform (Affymetrix, Santa Clara, USA) and five biological replicates per sample, we identified 823 upregulated and 289 downregulated genes (>2-fold) in double-knockout cells in comparison with the wild-type HCT-116 cell line. Regarding their DNA methylation profile, genes with increased expression in DNMT1/DNMT3B-defective cells were highly enriched in hypermethylated CpGs in HCT-116 and hypomethylated CpGs in DKO, determined by gene set enrichment analysis of ranked methylation levels (Fig. 8) . This observation was even more striking when probes located within the transcription start site or within the gene body were analyzed separately: promoter-associated positions, particularly within CpG islands, revealed a large methylation difference related to expression (Fig. 8) .
Finally, the 450K DNA methylation data might also be illustrated by cluster representations, as has been done extensively with the 1,505 CpG and 27K CpG DNA methylation microarrays. Although specific bioinformatic tools for the analyses of the 450K platform continue to be developed, we can already present a partial hierarchical clustering and a heatmap of the 450K DNA methylation data that enable normal colon mucosa, HCT-16 and DKO cells to be classified into distinct arms in the analysis (Fig. 9) . In addition to the internal consistency showing that the two normal colon mucosa samples (NC1 and NC2) cluster together, it is worth highlighting that the loss of DNA methylation in HCT-116 upon genetic disruption of DNMT1 and DNMT3 (DKO cells) shifts this sample to a more normal colon DNA methylation profile (Fig. 9) . This finding emphasizes the role of DNMTs in cellular transformation and the important aberrant DNA methylation changes that cancer cells undergo, such as occurs in the HCT-116 sample, which is isolated in a separate clustering arm (Fig. 9) . 
Materials and Methods

Human
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GenomeStudio normalizes data using different internal controls that are present on the HumanMethylation 450 BeadChip. It also normalizes data depending on internal background proves. CpG methylation differences were considered significant above a cut-off of a 0.6-fold change in the β value, unless specifically indicated otherwise.
DNA methylation clustering. We used the GenomeStudio (2010.3) Methylation module (1.8.5) software to generate heatmaps of clustered CpGs. Unsupervised hierarchical clustering of the 2,000 most variable B values (standard deviation >0.37) with a detection p value > 0.01 was performed, calculating Euclidian distances.
Conclusions
In the near future it will be possible to obtain a greater number of complete human DNA methylomes at a reasonable cost using the new emerging sequencing technologies. However, this is still an extremely challenging process and currently there are only a very few whole methylomes available in which every CpG has been counted. 18, 19 However, if researchers in the pure genome sequencing area are encountering difficulties in obtaining a massive number of completed human genomes in a cost-effective and user-friendly manner, those of us in the epigenetic field are even further behind-by several years. However, the development of a standardized comprehensive DNA methylation array that can be shared by different laboratories and agencies, employing a common methodology and bioinformatic package would be an important step in the right direction. Herein we have demonstrated that a newly available DNA methylation microarray (HumanMethylation450 BeadChip) might be an appropriate tool for this purpose. The 450K analyses of a colorectal tumorigenesis model that allows the study of normal and transformed cells in a variety of DNA methylation settings show that the data obtained are confirmed by the results of previously published studies in the area and provide biological, functional and technical validation of the new microarray. In the coming years, the application of the 450K DNA methylation platform in a userfriendly 12-sample per array format that requires only 500 ng of bisulfite-converted DNA per sample will provide extensive information about the DNA methylation landscape of human tumors. Most importantly, it might also be decisive in establishing that DNA methylation defects have a central role in other common human diseases and in finding answers to many currently unresolved biological questions. was performed to check for high molecular weight DNA fragments. 50 ng of DNA were loaded onto the gel using GeneRuler 1 kB as a ladder (Fermentas Cat. No. SM0314). The gel was run for 60 min at 120 mA. Samples showing bands or smears smaller than 10,000 bp were discarded. (D) DNA purity. 1 ul of normalized DNA was employed to measure the 260/280 and 260/230 ratios using a Nanodrop-1000. Samples showing RNA contamination (260/280 ratio >2) were discarded, and no samples with a 260/230 ratio less than 1 were accepted.
Bisulfite conversion. Bisulfite conversion of 600 ng of each sample was performed according to the manufacturer's recommendations for the Illumina Infinium Assay (EZ DNA methylation kit. Zymo Research. Cat. No. D5004). The incubation profile was 16 cycles at 95°C for 30 s, 50°C for 60 min and a final holding step at 4°C. The effectiveness of the bisulphite conversion was checked for three controls that were converted simultaneously with the samples. Enzymatically methylated Jurkat genomic DNA (New England Biolabs Cat. No. N4002S), genomic Jurkat DNA (New England Biolabs Cat. No. N4001S), and whole genome amplified genomic DNA were used as total methylated, intermediate-methylated and non-methylated controls. After bisulfite treatment, methylation-specific PCR 51 was performed on the control samples using a set of primers to amplify a 301 bp region of the 28s ribosomal DNA. (5'-AAA ATT CTT TTC AAC TTT CCC T-3' and 5'-GAG TGA ATA GGG AAG AGT TTA G-3'). PCR conditions were: 2 mM MgCl 2 at 95°C for 1 min, followed by 30 cycles at 95°C for 30 s, 58°C for 30 s and 72°C for 45 s, with a final step at 72°C for 10 min. Results were checked by loading 5 μl of the PCR control onto a 1.3% agarose gel using 1:100,000 dilution of SyberSafe and electrophoresing at 80 mA for 30 min.
DNA methylation assay. 4 μl of bisulfite-converted DNA were used for hybridization on Infinium HumanMethylation 450 BeadChip, following the Illumina Infinium HD Methylation protocol. This consisted of a whole genome amplification step followed by enzymatic end-point fragmentation, precipitation and resuspension. The resuspended samples were hybridized on HumanMethylation 450 BeadChips at 48°C for 16 h. Then unhybridized and non-specifically hybridized DNA were washed away, followed by a single nucleotide extension using the hybridized bisulfite-treated DNA as a template. The nucleotides incorporated were labeled with biotin (ddCTP and ddGTP) and 2,4-dinitrophenol (DNP) (ddATP and ddTTP). After the singlebase extension, repeated rounds of staining were performed with a combination of antibodies that differentiated DNP and biotin by fixing them different fluorophores. Finally the BeadChip was washed and protected in order to scan it.
Scanning beadchips. The Illumina HiScan SQ scanner is a two-color laser (532 nm/660 nm) fluorescent scanner with a 0.375 μm spatial resolution capable of exciting the fluorophores generated during the staining step of the protocol. The intensities of the images were extracted using GenomeStudio (2010.3) Methylation module (1.8.5) software. The methylation score for each CpG was represented as a b value according to the fluorescent intensity ratio. B values may take any value between 0 (nonmethylated) and 1 (completely methylated). 
